Medacta Expands its Hip and Shoulder Portfolio with M-Vizion Hip Femoral Modular Revision System and Long Humeral Diaphysis

EQS Group-Media / 2020-05-12 / 20:54 
 
*Media Release * 
 
*Medacta Expands its Hip and Shoulder Portfolio with M-Vizion Hip Femoral 
Modular Revision System and Long Humeral Diaphysis* 
 
_CASTEL SAN PIETRO_, _12 May 2020 _- Medacta announced today it has received 
clearance from the U.S. Food and Drug Administration (FDA) for its M-Vizion 
Femoral Revision System Extension for hip arthroplasty and its Long Humeral 
Diaphysis for shoulder joint replacement. 
 
"Medacta is constantly looking to expand our product offerings to better 
respond to patient needs. With our products we want to make surgeons more 
confident in the operating room and contribute to an enhanced patient 
experience," said Francesco Siccardi, CEO of Medacta. "As we continue to 
expand our product portfolio, we are committed to delivering solutions that 
can help optimize surgery, while minimizing recovery time and maximizing 
implant longevity." 
 
*M-Vizion Femoral Modular Revision System: New Options in Hip Revision 
Arthroplasty* 
These new products, part of Medacta's Revision Platform, further expand the 
Medacta Hip offering, adding a broader range of options to the M-Vizion 
Modular Stem. The educational offering on revision hip replacement is also 
expanding in parallel with the product portfolio. With an international 
network of Experts Surgeons, the M.O.R.E. Institute is leading education of 
revision techniques. Surgeons can master these techniques through the 
M.O.R.E. Institute's personalized high-level educational pathways. 
 
*Long Humeral Diaphysis: More Options for Complex Cases in Shoulder 
Replacement* 
The Long Humeral Diaphysis is indicated for shoulder replacement in complex 
cases or where there is a need for extended distal fixation. The implant, 
which is available in two lengths to accommodate patient needs, further 
expands the Medacta Shoulder System offering. With the Long Humeral 
Diaphysis, the Medacta Shoulder System is increasingly complete with a 
comprehensive range of short, standard and long stems. The Long Humeral 
Diaphysis will be introduced into the market in selected centers following 
the guidelines of Medacta's M.O.R.E. Excellence Clinical Program, a 
structured process that defines the steps and milestones that are integral 
to a safe introduction of new Medacta devices. 
 
*Important Milestones in a Challenging Period* 
The FDA clearance for the M-Vizion range extension and the Long Humeral 
Diaphysis is an important milestone, particularly considering the difficult 
period which the market is facing due to the Covid-19 impact. Medacta 
offices have quickly adapted to this new scenario. This successful FDA 
clearance has been possible thanks to the synergy of the Medacta 
organization, which has remained continually operational, resilient, and 
committed to the support of surgeons and patients worldwide. 
 
*Contact* 
Medacta International SA 
Gianluca Olgiati 
Senior Director Global Marketing 
Phone: [phone] 
[e-mail] 
 
*About Medacta* 
Medacta is an international company specialized in the design and production 
of innovative orthopaedic products and the development of accompanying 
surgical techniques for joint replacement, spine surgery, and sports 
medicine. Established in 1999 in Switzerland, Medacta's products and 
surgical techniques are characterized by innovation. Medacta is a pioneer in 
developing new offerings on the basis of minimally invasive surgical 
techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) 
technique for hip replacements. Medacta has leveraged its orthopaedic 
expertise and comprehensive understanding of the human body to develop the 
sophisticated MySolutions technology, which offers surgeons highly 
personalized pre-operative planning and implant placement methodologies by 
creating advanced personalized kinematic models and 3D planning tools for 
use in hip, knee, shoulder and spine procedures. 
 
Issuer: Medacta Group SA 
Key word(s): Research/Technology 
 
End of Corporate News 
Language:    English 
Company:     Medacta Group SA 
             Strada Regina 
             6874 Castel San Pietro 
             Switzerland 
Phone:       [phone] 
E-mail:      [e-mail], [e-mail] 
Internet:    www.medacta.com 
ISIN:        CH0468525222 
Listed:      SIX Swiss Exchange 
EQS News ID: 1042923 
 
End of News EQS Group Media 
 
1042923 2020-05-12 
 
 

(END) Dow Jones Newswires

May 12, 2020 14:55 ET (18:55 GMT)